BioMerieux (XPAR:BIM) Institutional Ownership : 18.83% (As of Apr. 30, 2024)

View and export this data going back to 2004. Start your Free Trial

What is BioMerieux Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioMerieux's institutional ownership is 18.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioMerieux's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioMerieux's Float Percentage Of Total Shares Outstanding is 0.00%.

BioMerieux Institutional Ownership Historical Data

The historical data trend for BioMerieux's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Institutional Ownership Chart

BioMerieux Historical Data

The historical data trend for BioMerieux can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	18.45	18.78	18.71	19.10	18.74	18.59	18.98	18.97	18.81	18.83

BioMerieux Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

BioMerieux (XPAR:BIM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BMXMF:USA BIMp:UK 0RUG:UK EYWN:Germany BIM:Austria

Address

Marcy l’Etoile, Lyon, FRA, 69280

Website

http://www.biomerieux.com

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

BioMerieux (XPAR:BIM) Headlines

No Headlines